Czech National Bank Buys 12,009 Shares of Gilead Sciences, Inc. $GILD

Czech National Bank lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 327,149 shares of the biopharmaceutical company’s stock after acquiring an additional 12,009 shares during the period. Czech National Bank’s holdings in Gilead Sciences were worth $40,154,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Corundum Trust Company INC bought a new stake in shares of Gilead Sciences in the 3rd quarter worth approximately $26,000. Howard Hughes Medical Institute purchased a new position in shares of Gilead Sciences during the second quarter valued at approximately $30,000. MTM Investment Management LLC raised its holdings in shares of Gilead Sciences by 176.0% during the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 176 shares in the last quarter. Kilter Group LLC purchased a new stake in Gilead Sciences in the second quarter worth $33,000. Finally, Board of the Pension Protection Fund bought a new stake in Gilead Sciences in the fourth quarter valued at $37,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $144.23, for a total value of $432,690.00. Following the transaction, the chief financial officer directly owned 179,191 shares of the company’s stock, valued at approximately $25,844,717.93. This represents a 1.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Friday, February 27th. The shares were sold at an average price of $144.79, for a total value of $1,447,900.00. Following the sale, the chief executive officer owned 642,308 shares in the company, valued at approximately $92,999,775.32. This represents a 1.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 309,280 shares of company stock worth $44,068,850. Corporate insiders own 0.27% of the company’s stock.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Arcellx in a large, strategic move to deepen its cell‑therapy franchise and obtain rights to anito‑cel; analyst commentary highlights anito‑cel as a meaningful revenue opportunity (GlobalData forecasts ~$658m sales by 2032), reinforcing the company’s long‑term growth story. Gilead doubles down on cell therapy
• Positive Sentiment: Gilead is buying Ouro Medicines for up to ~$2.18B to add OM336 (gamgertamig), a BCMAxCD3 T‑cell engager for autoimmune disease — a move that expands its inflammation/immunology pipeline and led to analyst and press coverage framing the deal as a second major bolt‑on after Arcellx. Gilead Eyes $2.2 Billion Autoimmune Push With Ouro Deal
• Positive Sentiment: Analyst/press takes (e.g., Barron’s, TipRanks) emphasize the strategic rationale — “immune reset” and broader immunology exposure — which likely bolstered investor confidence and buying interest following the deal announcements. Gilead to Buy Ouro Medicines for $2.2 Billion
• Neutral Sentiment: MaxCyte (a supplier/peer in cell therapy) reported a Q4 revenue miss — an industry data point investors may watch for supply or partner‑execution implications, but it does not directly change Gilead’s announced M&A strategy. MaxCyte Q4 Report
• Neutral Sentiment: Several short‑interest reports posted for March show large increases but contain erroneous/zeroed values (NaN/0), so there’s no clear short‑pressure signal to explain moves; treat the data as unreliable until exchanges update filings.
• Neutral Sentiment: Other sector news (Weave Bio advisory board, broad market mover roundups) is background noise and unlikely to be a primary driver of GILD’s intraday move. Weave Bio Advisory Board

Analyst Upgrades and Downgrades

Several research analysts have commented on GILD shares. Needham & Company LLC restated a “buy” rating and issued a $170.00 price objective on shares of Gilead Sciences in a report on Monday, February 23rd. Leerink Partners lifted their price objective on Gilead Sciences from $146.00 to $148.00 and gave the company an “outperform” rating in a research report on Wednesday, February 11th. Rothschild & Co Redburn lifted their price target on Gilead Sciences from $159.00 to $170.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. The Goldman Sachs Group increased their price objective on Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a report on Thursday, January 8th. Finally, Morgan Stanley upped their target price on shares of Gilead Sciences from $150.00 to $171.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Twenty-four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $157.62.

Gilead Sciences Trading Up 0.1%

Gilead Sciences stock opened at $138.26 on Thursday. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $157.29. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The business’s fifty day simple moving average is $143.59 and its two-hundred day simple moving average is $128.39. The company has a market capitalization of $171.61 billion, a price-to-earnings ratio of 20.42, a price-to-earnings-growth ratio of 1.81 and a beta of 0.37.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.Gilead Sciences’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be paid a $0.82 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Friday, March 13th. Gilead Sciences’s payout ratio is currently 48.45%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.